DLL1 Antibody (251123) [Unconjugated]

NL007) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips." > NL007) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips." title="DLL1 was detected in immersion fixed HepG2 human hepatocellular carcinoma cell line using Mouse Anti-Human DLL1 Monoclonal Antibody (Catalog # MAB18181) at 25 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips." />

DLL1 was detected in immersion fixed HepG2 human hepatocellular carcinoma cell line using Mouse Anti-Human DLL1 Monoclonal Antibody (Catalog # MAB18181) at 25 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # <a class=

VC001). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (CTS013). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm in cancer cells. Staining was performed using our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents." > VC001). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (CTS013). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm in cancer cells. Staining was performed using our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents." title="DLL1 was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using Mouse Anti-Human DLL1 Monoclonal Antibody (Catalog # MAB18181) at 1.7 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (VC001). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (CTS013). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm in cancer cells. Staining was performed using our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents." />

DLL1 was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using Mouse Anti-Human DLL1 Monoclonal Antibody (Catalog # MAB18181) at 1.7 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (<a class=

Expression pattern of DLL1 in the developing cochlea of primates. (a) In E87 cochlea, no expression of DLL1 was detected in either ATOH1-positive hair cells or SOX2-positive supporting cells. (b) In contrast, a relatively weak expression of DLL1 was observed in ATOH1-positive hair cells in the E92 cochlea. (c) In E96 cochlea, the expression of DLL1 in hair cells became more pronounced. (d–h) After E101, DLL1 was continuously expressed in hair cells. Nuclei were counterstained with Hoechst (blue). Scale bar: 20 μm. IHC, inner hair cell; OHC, the outer hair cell. (a,b,d,g,h): basal turn, (c,e,f): middle turn. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/37351521), licensed under a CC-BY license. Not internally tested by R&D Systems.

Expression pattern of DLL1 in the developing cochlea of primates. (a) In E87 cochlea, no expression of DLL1 was detected in either ATOH1-positive hair cells or SOX2-positive supporting cells. (b) In contrast, a relatively weak expression of DLL1 was observed in ATOH1-positive hair cells in the E92 cochlea. (c) In E96 cochlea, the expression of DLL1 in hair cells became more pronounced. (d–h) After E101, DLL1 was continuously expressed in hair cells. Nuclei were counterstained with Hoechst (blue). Scale bar: 20 μm. IHC, inner hair cell; OHC, the outer hair cell. (a,b,d,g,h): basal turn, (c,e,f): middle turn. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/37351521), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Hu
• Applications: IHC, ICC/IF
• Clone: 251123
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Concentration: LYOPH

DLL1 Antibody (251123) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human DLL1
  Ser22-Gly540
  Accession # AAG09716
• Specificity: Detects human DLL1 in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) DLL3 or rhDLL4 is observed.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Gene: DLL1
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry 8-25 ug/mL
  • Immunohistochemistry 1.7-25 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for DLL1 Antibody (251123) [Unconjugated]

• delta (Drosophila)-like 1
• Delta 1
• Delta
• Delta1
• delta-like 1 (Drosophila)
• delta-like protein 1
• DL1
• DLL1
• Drosophila Delta homolog 1
• H-Delta-1

Background

Delta-like protein 1 (DLL1) is a 90‑100 kDa type I transmembrane protein that belongs to the Delta/Serrate/Lag-2 (DSL) family of Notch ligands. Mature human DLL1 consists of a 528 amino acid (aa) extracellular domain (ECD) with one DSL domain and eight EGF-like repeats, a 23 aa transmembrane segment, and a 155 aa cytoplasmic domain (1). Within the ECD, human DLL1 shares 91% aa sequence identity with mouse and rat DLL1. It shares 26%, 37%, and 54% aa sequence identity with DLL2, 3, and 4, respectively. A 60 kDa ECD fragment released by ADAM9, 12, or 17 mediated proteolysis, promotes the proliferation of hematopoietic progenitor cells (2, 3). The residual membrane-bound portion of DLL1 can be cleaved by presenilin-dependent gamma -secretase, enabling the cytoplasmic domain to migrate to the nucleus (4). DLL1 localizes to adherens junctions on neuronal processes through its association with the scaffolding protein MAGI1 (5). DLL1 is widely expressed, and it plays an important role in embryonic somite formation, cochlear hair cell differentiation, plus B and T lymphocyte differentiation (6‑11). The upregulation of DLL1 in arterial endothelial cells following injury or angiogenic stimulation is central to postnatal arteriogenesis (12). DLL1 is also overexpressed in cervical carcinoma and glioma and contributes to tumor progression (1, 13).

1. Gray, G.E. et al. (1999) Am. J. Pathol. 154:785. 
2. Dyczynska, E. et al. (2007) J. Biol. Chem. 282:436. 
3. Karanu, F.N. et al. (2001) Blood 97:1960. 
4. Ikeuchi, T. and S.S. Sisodia (2003) J. Biol. Chem. 278:7751. 
5. Mizuhara, E. et al. (2005) J. Biol. Chem. 280:26499. 
6. Takahashi, Y. et al. (2003) Development 130:4259. 
7. Teppner, I. et al. (2007) BMC Dev. Biol. 7:68.
8. Kiernan, A.E. et al. (2005) Development 132:4353.
9. Schmitt, T.M. and J.C. Zuniga-Pflucker (2002) Immunity 17:749.
10. Hozumi, K. et al. (2004) Nat. Immunol. 5:638.
11. Santos, M.A. et al. (2007) Proc. Natl. Acad. Sci. 104:15454.
12. Limbourg, A. et al. (2007) Circ. Res. 100:363.
13. Purow, B.W. et al. (2005) Cancer Res. 65:2353.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for DLL1 Antibody (MAB18181)(4)

Publications using MAB18181

• Damelin M, Geles KG, Follettie MT, Yuan P, Baxter M, Golas J, Dijoseph JF, Karnoub M, Huang S, Diesl V, Behrens C, Choe SE, Rios C, Gruzas J, Sridharan L, Dougher M, Kunz A, Hamann PR, Evans D, Armellino D, Khandke K, Marquette K, Tchistiakova L, Boghaert ER, Abraham RT, Wistuba II, Zhou BB Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells. Cancer Res., 2011-05-03;71(12):4236-46. 2011-05-03 [PMID: 21540235] (IHC-Fr, Human)
• Xing F, Okuda H, Watabe M, Kobayashi A, Pai SK, Liu W, Pandey PR, Fukuda K, Hirota S, Sugai T, Wakabayshi G, Koeda K, Kashiwaba M, Suzuki K, Chiba T, Endo M, Mo YY, Watabe K Hypoxia-induced Jagged2 promotes breast cancer metastasis and self-renewal of cancer stem-like cells. Oncogene, 2011-04-18;30(39):4075-86. 2011-04-18 [PMID: 21499308] (IHC-P, Human)
• Rodrigues KM, Oliveira MP, Maretti-Mira AC, Oliveira-Neto MP, Mattos MS, Silva L, Soares DA, Dolci EL, Perico RA, Pirmez C Influence of the Notch system in the therapeutic response of American tegumentary leishmaniasis. Br. J. Dermatol., 2011-05-17;164(6):1228-34. 2011-05-17 [PMID: 21299543] (IHC-Fr, Human)
• Lasagni L, Ballerini L, Angelotti ML Notch activation differentially regulates renal progenitors proliferation and differentiation toward the podocyte lineage in glomerular disorders. Stem Cells, 2010-09-01;28(9):1674-85. 2010-09-01 [PMID: 20680961] (ICC, Human)

Bioinformatics

• Gene Symbol: DLL1
• Uniprot:
  • AAG09716()